Compounds > 7-n-(4-hydroxyphenyl)mitomycin c
Page last updated: 2024-09-22

7-n-(4-hydroxyphenyl)mitomycin c

Cross-References

ID SourceID
PubMed CID14136266
MeSH IDM0088831

Synonyms (8)

Synonym
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6-((4-hydroxyphenyl)amino)-8a-methoxy-5-methyl-, (1as-(1aalpha,8beta,8aalpha,8balpha))-
7-n-(4-hydroxyphenyl)mitomycin c
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6-(p-hydroxyanilino)-8a-methoxy-5-methyl-, 8-carbamate (ester)
n(6)-4-hydroxyphenylmitomycin c
70343-57-6
[(4s,6s,7r,8s)-11-(4-hydroxyanilino)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
PD161200
AKOS040750001

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (96.55)18.7374
1990's1 (3.45)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
dithiothreitol[no description available]medium101,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
sodium borohydride[no description available]medium10inorganic sodium salt;
metal tetrahydridoborate
mitomycin[no description available]medium290mitomycinalkylating agent;
antineoplastic agent
methylnitronitrosoguanidine[no description available]medium20nitroso compoundalkylating agent
enng[no description available]medium20
adenine[no description available]medium106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
n(6)-((dimethylamino)methylene)mitomycin c[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Ache0low10
Adenocarcinoma0low50
Adenocarcinoma, Basal Cell0low50
Adenocarcinoma, Granular Cell0low50
Adenocarcinoma, Oxyphilic0low50
Adenocarcinoma, Tubular0low50
Adenoma, Malignant0low50
Anorexia0low30
Benign Neoplasms0low40
Biliary Tract Cancer0low10
Biliary Tract Neoplasms0low10
Breast Cancer0low20
Breast Carcinoma0low20
Breast Neoplasms0low20
Breast Tumors0low20
Cancer0low40
Cancer of Biliary Tract0low10
Cancer of Breast0low20
Cancer of Colon0low50
Cancer of Esophagus0low10
Cancer of Liver0low10
Cancer of Lung0low90
Cancer of Ovary0low20
Cancer of Pancreas0low10
Cancer of Prostate0low10
Cancer of Stomach0low60
Cancer of the Biliary Tract0low10
Cancer of the Breast0low20
Cancer of the Colon0low50
Cancer of the Esophagus0low10
Cancer of the Liver0low10
Cancer of the Lung0low90
Cancer of the Ovary0low20
Cancer of the Pancreas0low10
Cancer of the Prostate0low10
Cancer of the Stomach0low60
Cancer, Hepatocellular0low10
Carcinoma0low20
Carcinoma, Anaplastic0low20
Carcinoma, Bronchial0low10
Carcinoma, Bronchogenic0low10
Carcinoma, Cribriform0low50
Carcinoma, Epidermoid0low20
Carcinoma, Granular Cell0low50
Carcinoma, Oat Cell0low10
Carcinoma, Planocellular0low20
Carcinoma, Small Cell0low10
Carcinoma, Spindle-Cell0low20
Carcinoma, Squamous0low20
Carcinoma, Squamous Cell0low20
Carcinoma, Tubular0low50
Carcinoma, Undifferentiated0low20
Carcinomatosis0low20
Colon Cancer0low50
Colon Neoplasms0low50
Colonic Cancer0low50
Colonic Neoplasms0low50
Delayed Hypersensitivity0low10
Dysembryoma0low10
Emesis0low20
Epithelial Neoplasms, Malignant0low20
Epithelial Tumors, Malignant0low20
Epithelioma0low20
Esophageal Cancer0low10
Esophageal Neoplasms0low10
Esophagus Cancer0low10
Esophagus Neoplasm0low10
Experimental Hepatoma0low10
Experimental Hepatomas0low10
Experimental Leukemia0low10
Experimental Leukemias0low10
Experimental Liver Neoplasms0low10
Experimental Neoplasms0low30
Fever0low10
Fibrosarcoma0low10
Gastric Cancer0low60
Gastric Cancer, Familial Diffuse0low60
Gastric Neoplasms0low60
Hepatic Cancer0low10
Hepatic Neoplasms0low10
Hepatocellular Cancer0low10
Hepatoma, Experimental0low10
Hepatoma, Morris0low10
Hepatoma, Novikoff0low10
Hepatomas, Experimental0low10
Human Mammary Carcinoma0low20
Hypersensitivity, Delayed0low10
Hypersensitivity, Tuberculin-Type0low10
Hypersensitivity, Type IV0low10
Leukemia Model, Animal0low10
Leukemia P3880low50
Leukemia, Experimental0low10
Leukemias, Experimental0low10
Liver Cancer0low10
Liver Neoplasms0low10
Liver Neoplasms, Experimental0low10
Lung Cancer0low90
Lung Neoplasms0low90
Malignancy0low40
Malignant Epithelial Neoplasms0low20
Malignant Neoplasm of Breast0low20
Malignant Neoplasms0low40
Malignant Tumor of Breast0low20
Mammary Cancer0low20
Mammary Carcinoma, Human0low20
Mammary Neoplasm, Human0low20
Mammary Neoplasms, Human0low20
Nausea0low40
Neoplasia0low40
Neoplasm0low40
Neoplasms0low40
Neoplasms, Benign0low40
Neoplasms, Biliary Tract0low10
Neoplasms, Breast0low20
Neoplasms, Colonic0low50
Neoplasms, Esophageal0low10
Neoplasms, Experimental0low30
Neoplasms, Experimental Liver0low10
Neoplasms, Gastric0low60
Neoplasms, Hepatic0low10
Neoplasms, Liver0low10
Neoplasms, Lung0low90
Neoplasms, Malignant Epithelial0low20
Neoplasms, Ovarian0low20
Neoplasms, Pancreatic0low10
Neoplasms, Prostate0low10
Neoplasms, Prostatic0low10
Neoplasms, Pulmonary0low90
Neoplasms, Stomach0low60
Oat Cell Carcinoma0low10
Ovarian Cancer0low20
Ovarian Neoplasms0low20
Ovary Cancer0low20
Ovary Neoplasms0low20
P388D(1) Leukemia0low50
Pain0low10
Pain, Burning0low10
Pain, Crushing0low10
Pain, Migratory0low10
Pain, Radiating0low10
Pain, Splitting0low10
Pancreas Cancer0low10
Pancreas Neoplasms0low10
Pancreatic Cancer0low10
Pancreatic Neoplasms0low10
Pleurisy0low10
Pleuritis0low10
Pregnancy0low10
Prostate Cancer0low10
Prostate Neoplasms0low10
Prostatic Cancer0low10
Prostatic Neoplasms0low10
Pulmonary Cancer0low90
Pulmonary Neoplasms0low90
Pyrexia0low10
Sarcoma 1800low10
Sarcoma 180, Crocker0low10
Small Cell Carcinoma0low10
Squamous Cell Carcinoma0low20
Stomach Cancer0low60
Stomach Neoplasms0low60
Suffering, Physical0low10
Teratoid Tumor0low10
Teratoma0low10
Teratoma, Benign0low10
Teratoma, Cystic0low10
Teratoma, Immature0low10
Teratoma, Malignant0low10
Teratoma, Mature0low10
Thrombocytopenia0low10
Thrombopenia0low10
Tuberculin-Type Hypersensitivity0low10
Tumors0low40
Tumors, Breast0low20
Type IV Hypersensitivity0low10
Vomiting0low20

Research Highlights

Safety/Toxicity (1)

ArticleYear
Comparison of the hematologic toxicity of 7-N-(p-hydroxyphenyl),-mitomycin C and mitomycin C.
Gan, Volume: 72, Issue: 6		1981
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (3)

ArticleYear
[Studies on the physiological disposition and pharmacokinetics of 7-N-(p-hydroxyphenyl)-mitomycin C].
The Japanese journal of antibiotics, Volume: 35, Issue: 8		1982
[Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
Gan to kagaku ryoho. Cancer & chemotherapy, Volume: 9, Issue: 8		1982
Antitumor activity and pharmacokinetics of 7-N-(p-hydroxyphenyl)mitomycin C in human tumor xenografts transplanted into nude mice.
The Journal of antibiotics, Volume: 38, Issue: 3		1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]